Based on research conducted at UMass Medical School, TNX-4800 is a long-acting monoclonal antibody now being licensed to Tonix Pharmaceuticals for further development as single-dose, seasonal protection against Lyme disease. The antibody targets the bacteria that causes Lyme disease, blocking its transmission from infected ticks and providing immunity without requiring the body to produce its own antibodies.
A previously conducted Phase 1 study in healthy volunteers showed TNX-4800 is safe, well-tolerated, and remains in the bloodstream throughout the tick season, supporting advancement to an adaptive Phase 2/3 trial. If successful, TNX-4800 could become the first FDA-approved preventive treatment for Lyme disease.
-1.jpg)
